Overview

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

Status:
Completed
Trial end date:
2016-03-31
Target enrollment:
Participant gender:
Summary
This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.
Phase:
Phase 4
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Omalizumab